Zuclopenthixol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Zuclopenthixol: Retinal dystrophy with or without extraocular anomalies
One-Sentence Summary
Zuclopenthixol is a thioxanthene antipsychotic, originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications currently support this prediction, so it is a computational hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the curated data compiled for this report. Based on general pharmacological knowledge, zuclopenthixol is a thioxanthene antipsychotic that acts mainly as a dopamine D1/D2 antagonist, with additional 5-HT2A and alpha-1 adrenergic antagonism. Its efficacy in schizophrenia comes from this receptor blockade.
For retinal dystrophy, no mechanistic link has been established. These disorders are largely monogenic, structural or degenerative conditions, and there is no known dopaminergic mechanism that receptor antagonism would correct. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The prediction should be treated as a hypothesis, not as supported evidence.
Other predicted indications show the same pattern. All eight further predictions (scores 99.98–0.9999) also lack trials and literature, and they are L5 with a Hold recommendation:
| Rank | Predicted Disease | Mechanistic Assessment |
|---|---|---|
| 2 | Hydranencephaly | No plausible link; receptor antagonism cannot restore absent brain tissue |
| 3 | Congenital disorder of glycosylation with defective fucosylation | No action on glycosylation pathways |
| 4 | Charcot-Marie-Tooth disease, demyelinating, type 1G | No link; antipsychotic neurological adverse effects argue for caution |
| 5 | Myopia, X-linked | Dopamine antagonism would be expected to act in the unfavourable direction |
| 6 | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | Developmental malformation; no link |
| 7 | Syndromic myopia | Weak and unfavourable link via retinal dopamine |
| 8 | Myopia 26, X-linked, female-limited | Same unfavourable direction as other myopia entries |
| 9 | Atypical glycine encephalopathy | No clear link; seizure-threshold lowering is a concern |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 44808 | Clopixol 50mg Injection | Vial of 1 ml injection | Not stated in the records |
| 40031 | Clopixol 100mg Injection | Vial of 2 ml injection | Not stated in the records |
| 37606 | Clopixol-Acuphase Injection | Vial of 1 ml injection | Not stated in the records |
All three licences are valid single-ingredient injectable products from Lundbeck India Pvt Ltd.
Safety Considerations
Please refer to the package insert for safety information.
Note: no drug-interaction records were found in the data compiled for this report, and no knowledge-graph contraindications were listed. This should not be read as evidence of safety. Some predicted indications also raise specific concerns. Antipsychotics can cause extrapyramidal symptoms and can lower the seizure threshold, which matters for neuropathy and for encephalopathy with seizures.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5). There are no clinical trials or publications, and no plausible mechanism links dopamine and serotonin receptor antagonism to retinal dystrophy. The same holds for the other eight predicted indications, and for the myopia entries the theoretical direction of effect is unfavourable.
To proceed, the following is needed:
- Package insert warnings and contraindications for the India products (currently blocking safety screening)
- Curated mechanism of action data for zuclopenthixol
- Preclinical or mechanistic studies showing a biological link to retinal dystrophy, such as retinal models or a dopaminergic role in the specific genetic forms
- A systematic literature and trial search to confirm that no supporting evidence exists
- Route compatibility assessment (current India products are injectable only), and the intended-use population and risk-benefit review for a chronic genetic eye disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.